Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Comparing safety and efficacy of Bevacizumab, Ranibizumab and Ranibizumab biosimilar in Retinopathy of prematurity

Eye volume 39, pages 1688–1693 (2025)Cite this article

Subjects

Abstract

Purpose

To compare the safety and efficacy of Bevacizumab, Ranibizumab and Ranibizumab biosimilar in treatment of Retinopathy of prematurity (ROP)

Methods

Retrospective study that included newborns with type 1 ROP who received intravitreal Bevacizumab (Avastin) or Ranibizumab (Accentrix) or Ranibizumab biosimilar (Razumab). Babies were followed up as per protocol and retreatment with laser or repeat anti vascular endothelial growth factor (VEGF) was done in case of reactivation and surgery in case of progression to traction. Outcome measures include need for retreatment, proportion of eyes achieving vascularization up to ora and adverse events

Results

148 eyes of 75 babies, received intravitreal injection of which 139 eyes of 70 babies were included in our analysis. 68 eyes received bevacizumab (IVB), 31 eyes received Accentrix (IVA), 40 eyes received Razumab(IVR). The rate of retreatment was 17.6%, 32.2% and 25% for IVB, IVA and IVR respectively (p = 0.1). IVB group showed a significantly delayed reactivation (p < 0.001), while Ranibizumab and its biosimilar Razumab were comparable (p = 0.17). Vascularization up to ora was observed in 60%, 61% and 50% eyes (p = 0.76) at a median of 27, 28 and 24 weeks post-treatment (p = 0.09) in IVB, IVA and IVR groups respectively. No eyes developed intraocular inflammation or cataract.

Conclusion

All three drugs were similar in their efficacy and safety profile with bevacizumab showing a later reactivation.

Access through your institution
Buy or subscribe

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Graphical representation of outcomes of treatment with IVB, IVA, and IVR.

Similar content being viewed by others

Data availability

The data pertaining to this manuscript are included in the article and any additional data can be made available on request.

References

  1. Early Treatment For Retinopathy Of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol. 2003;121:1684–94.

    Article  Google Scholar 

  2. Shah PK, Narendran V, Tawansy KA, Raghuram A, Narendran K. Intravitreal bevacizumab (Avastin) for post laser anterior segment ischemia in aggressive posterior retinopathy of prematurity. Indian J Ophthalmol. 2007;55:75–6.

    Article  PubMed  Google Scholar 

  3. Chiang MF, Quinn GE, Fielder AR, Ostmo SR, Paul Chan RV, Berrocal A, et al. International classification of retinopathy of prematurity, Third Edition. Ophthalmology. 2021;128:e51–e68.

    Article  PubMed  Google Scholar 

  4. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity. Preliminary results. Arch Ophthalmol. 1988;106:471–9.

  5. Pierce EA, Foley ED, Smith LE. Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity. Arch Ophthalmol. 1996;114:1219–28.

    Article  CAS  PubMed  Google Scholar 

  6. Kong L, Bhatt AR, Demny AB, Coats DK, Li A, Rahman EZ, et al. Pharmacokinetics of bevacizumab and its effects on serum VEGF and IGF-1 in infants with retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2015;56:956–61.

    Article  CAS  PubMed  Google Scholar 

  7. Fidler M, Fleck BW, Stahl A, Marlow N, Chastain JE, Li J, et al. RAINBOW study group†. Ranibizumab population pharmacokinetics and free VEGF pharmacodynamics in preterm infants with retinopathy of prematurity in the RAINBOW trial. Transl Vis Sci Technol. 2020;9:43.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Enríquez AB, Avery RL, Baumal CR. Update on anti-vascular endothelial growth factor safety for retinopathy of prematurity. Asia Pac J Ophthalmol. 2020;9:358–68.

    Article  Google Scholar 

  9. Patel NA, Acaba-Berrocal LA, Hoyek S, Fan KC, Martinez-Castellanos MA, Baumal CR, et al. Retinopathy of prematurity injection consortium. practice patterns and outcomes of intravitreal anti-VEGF injection for retinopathy of prematurity: an international multicenter study. Ophthalmology. 2022;129:1380–8.

    Article  PubMed  Google Scholar 

  10. Xu L, Lu T, Tuomi L, Jumbe N, Lu J, Eppler S, et al. Pharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration: a population approach. Invest Ophthalmol Vis Sci. 2013;54:1616–24.

    Article  CAS  PubMed  Google Scholar 

  11. Avery RL, Castellarin AA, Steinle NC, Dhoot DS, Pieramici DJ, See R, et al. Systemic Pharmacokinetics and Pharmacodynamics of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab. Retina. 2017;37:1847–58.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Wu WC, Shih CP, Lien R, Wang NK, Chen YP, Chao AN, et al. Serum vascular endothelial growth factor after bevacizumab or ranibizumab treatment for retinopathy of prematurity. Retina. 2017;37:694–701.

    Article  PubMed  Google Scholar 

  13. Stahl A, Lepore D, Fielder A, Fleck B, Reynolds JD, Chiang MF, et al. Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial. Lancet. 2019;394:1551–9.

    Article  CAS  PubMed  Google Scholar 

  14. Darwish D, Chee RI, Patel SN, Jonas K, Ostmo S, Campbell JP, et al. Anti-Vascular Endothelial Growth Factor and the Evolving Management Paradigm for Retinopathy of Prematurity. Asia Pac. J Ophthalmol. 2018;7:136–44.

    Google Scholar 

  15. Celiker H, Sahin O. Angiographic findings in cases with a history of severe retinopathy of prematurity treated with anti-VEGFs: Follow-up to age 6 years. Int Ophthalmol. 2022;42:1317–37.

    Article  PubMed  Google Scholar 

  16. Chan JJT, Lam CPS, Kwok MKM, Wong RLM, Lee GKY, Lau WWY, et al. Risk of recurrence of retinopathy of prematurity after initial intravitreal ranibizumab therapy. Sci Rep. 2016;6:27082.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Adams GG, Bunce C, Xing W, Butler L, Long V, Reddy A, et al. Retinopathy of prematurity in the United Kingdom:Retreatment rates, visual and structural 1-year outcomes. Eye. 2018;32:1752–9.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Ji MH, Moshfeghi DM, Shields RA, Bodnar Z, Ludwig CA, Callaway NF, et al. Conserved regression patterns of retinopathy of prematurity after intravitreal ranibizumab:A class effect. Eur J Ophthalmol. 2021;31:2135–40.

    Article  PubMed  Google Scholar 

  19. Lyu J, Zhang Q, Chen CL, Xu Y, Ji XD, Li JK, et al. Recurrence of retinopathy of prematurity after intravitreal ranibizumab monotherapy:Timing and risk factors. Invest Ophthalmol Vis Sci. 2017;58:1719–25.

    Article  PubMed  Google Scholar 

  20. Blair M, Gonzalez JMG, Snyder L, Schechet S, Greenwald M, Shapiro M, et al. Bevacizumab or laser for aggressive posterior retinopathy of prematurity. Taiwan J Ophthalmol. 2018;8:243–8.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Tong Q, Yin H, Zhao M, Li X, Yu W. Outcomes and prognostic factors for aggressive posterior retinopathy of prematurity following initial treatment with intravitreal ranibizumab. BMC Ophthalmol. 2018;18:150.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Blair M, Rodriguez S, Schechet S, ShapiroW M. Aggressive Posterior Retinopathy of Prematurity (APROP). in C Wu, W-C Lam (eds.), A Quick Guide to Pediatric Retina (First edition, 43-51) Springer Nature Singapore Pte Ltd. 2021

  23. Mintz-Hittner HA, Kennedy KA, Chuang AZ. BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011;364:603–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Ekinci DY, Vural AD, Bayramoglu SE, Onur IU, Hergunsel GO. Assessment of vascular leakage and its development with FFA among patients treated with intravitreal anti-VEGF due to aggressive posterior ROP. Int Ophthalmol. 2019;39:2697–705.

    Article  PubMed  Google Scholar 

  25. Diggikar S, Gurumoorthy P, Trif P, Mudura D, Nagesh NK, Galis R, et al. Retinopathy of prematurity and neurodevelopmental outcomes in preterm infants: A systematic review and meta-analysis. Front Pediatr. 2023;11:1055813.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Marlow N, Reynolds JD, Lepore D, Fielder AR, Stahl A, Hao H, et al. Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): five-year outcomes of a randomised trial. EClinicalMedicine. 2024;71:102567.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Honda S, Hirabayashi H, Tsukahara Y, Negi A. Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol. 2008;246:1061–3.

    Article  CAS  PubMed  Google Scholar 

  28. Zepeda-Romero L, Liera-Garcia J, Gutiérrez-Padilla J, et al. Paradoxical vascular–fibrotic reaction after intravitreal bevacizumab for retinopathy of prematurity. Eye. 2010;24:931–3.

    Article  CAS  PubMed  Google Scholar 

  29. Yonekawa Y, Wu WC, Nitulescu CE, Chan RVP, Thanos A, Thomas BJ, et al. Progressive retinal detachment in infants with retinopathy of prematurity treated with intravitreal bevacizumab or ranibizumab. Retina. 2018;38:1079–83.

    Article  CAS  PubMed  Google Scholar 

  30. Maitra P, Prema S, Narendran V, Shah PK. Safety and efficacy of intravitreal anti vascular endothelial growth factor for severe posterior retinopathy of prematurity with flat fibrovascular proliferation. World J Clin Pediatr. 2023;12:220–9.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Wood EH, Rao P, Moysidis SN, Dedania VS, Elman MJ, Drenser KA, et al. Fellow Eye Anti-VEGF ‘Crunch’ Effect in Retinopathy of Prematurity. Ophthalmic Surg Lasers Imaging Retina. 2018;49:e102–e104.

    Article  PubMed  Google Scholar 

  32. Guidelines on evaluation of biosimilars. http://www.who.int/publications/m/item/guidelines-on-evaluation-of-biosimilars; Accessed June 10, 2024

  33. Prajapati V, Choudhary T, Chauhan W, Shah S, Handa R, Jahan B, et al. Efficacy of a biosimilar ranibizumab monotherapy for the treatment of retinopathy of prematurity. Indian J Ophthalmol. 2023;71:411–5.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Ratra D, Roy K, Giridhar S, Madaan S, Sankara Nethralaya Vitreoretinal Study Group. Comparison between ranibizumab biosimilar, innovator ranibizumab and bevacizumab in a real-world situation. Ophthalmol Ther. 2022;11:135–149.

  35. Sharma A, Hafeez Faridi M, Kumar N, Parachuri N, Sharma R, Kuppermann BD, et al. Immunogenicity and efficacy after switching from original Ranibizumab to a Ranibizumab biosimilar: real-world data. Eye. 2020;34:1008–9.

    Article  PubMed  Google Scholar 

  36. Chakraborty S, Sheth JU. Efficacy of an Indian Bevacizumab BIOSimilar (BEVATAS) for Type 1 and Aggressive Posterior Retinopathy of Prematurity (BIOS-ROP Study). Clin Ophthalmol. 2024;18:61–68.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Shukla R, Murthy GVS, Gilbert C, Vidyadhar B, Mukpalkar S. Operational guidelines for ROP in India: A summary. Indian J Ophthalmol. 2020;68:S108–S114.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Vitreoretina Services, Aravind, Eye Hospital, Chennai, Tamil Nadu, India

    Puja Maitra

  2. Ophthalmology Resident, Aravind Eye Hospital and Postgraduate Institute of Ophthalmology, Coimbatore, Tamil Nadu, India

    Sujay Jaju

  3. Department of Paediatric Retina and Ocular Oncology, Aravind Eye Hospital and Postgraduate Institute of Ophthalmology, Coimbatore, Tamil Nadu, India

    Kushal U. Agrawal, Abhishek Das, Prema Subramaniam, Narendran Venkatapathy & Parag K. Shah

Authors
  1. Puja Maitra
    View author publications

    Search author on:PubMed Google Scholar

  2. Sujay Jaju
    View author publications

    Search author on:PubMed Google Scholar

  3. Kushal U. Agrawal
    View author publications

    Search author on:PubMed Google Scholar

  4. Abhishek Das
    View author publications

    Search author on:PubMed Google Scholar

  5. Prema Subramaniam
    View author publications

    Search author on:PubMed Google Scholar

  6. Narendran Venkatapathy
    View author publications

    Search author on:PubMed Google Scholar

  7. Parag K. Shah
    View author publications

    Search author on:PubMed Google Scholar

Contributions

All Authors have made direct and substantial contributions to the manuscript. Concept and design: Parag K. Shah, Data collection: Sujay Jaju, Kushal U. Agrawal, Abhishek Das, Prema Subramaniam, Analysis an interpretation: Puja Maitra, Manuscript writing: Puja Maitra Manuscript editing/ revision: Parag K. Shah, Supervision: Parag K. Shah, Narendran Venkatapathy.

Corresponding author

Correspondence to Parag K. Shah.

Ethics declarations

Competing interests

The authors declares that there is no conflict of interest regarding the publication of this article.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Maitra, P., Jaju, S., Agrawal, K.U. et al. Comparing safety and efficacy of Bevacizumab, Ranibizumab and Ranibizumab biosimilar in Retinopathy of prematurity. Eye 39, 1688–1693 (2025). https://doi.org/10.1038/s41433-025-03735-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41433-025-03735-z

This article is cited by

Search

Advanced search

Quick links